What is the revenue and EPS growth rate for Beyond Air year over year?

What is Beyond Air's gross profit margin?

What were the key takeaways from Beyond Air's earnings call?

What is Beyond Air's latest dividend and current dividend yield?

What does Beyond Air do and what are its main business segments?

What guidance did Beyond Air's management provide for the next earnings period?

Did Beyond Air beat or miss consensus estimates last quarter?

What were the key takeaways from Beyond Air’s earnings call?

- **Revenue Growth**: 105% YoY to $2.2M, driven by Gen I LungFit PH adoption
- **Gen II Launch**: FDA approval expected by end-2026 with enhanced transport capabilities
- **Strategic Restructuring**: NeuroNOS sale provides $31.5M milestone potential
- **Financial Health**: $17.8M cash, 36% OpEx reduction, 13.6% gross margin
- **Pipeline Progress**: Beyond Cancer Phase Ib trial for nitric oxide therapy in glioblastoma and autism

**【CEO Summary Section】**
Beyond Air reported a 105% year-over-year increase in revenue to $2.2 million for Q3 2026, driven by strong adoption of the LungFit PH system in 45+ hospitals globally. The company expects FDA approval for the second-generation (Gen II) LungFit PH system by end-2026, with features including reduced size, transport compatibility, and extended service intervals. Beyond Air sold its NeuroNOS subsidiary to XTL Biopharmaceuticals for a 19.9% stake and $31.5 million in potential milestone payments, freeing capital for core nitric oxide therapy development.

**【CFO Financial Commentary】**
Q3 2026 financial highlights include:
- GAAP net loss of $7.3 million (-45% YoY)
- Operating expenses down 36% YoY to $6.9 million
- Cash balance of $17.8 million post $4.5 million equity raise
- Cash burn of $4.3 million Q3, with runway into 2027
- Gross margin improved to 13.6% (vs. -18.2% Q3 2025)

**【Q&A Key Highlights】**
1. **Gen II Launch Readiness**: FDA approval expected by end-2026; pre-launch inventory build underway
2. **Commercial Momentum**: 90%+ customer retention, 50%+ multi-year contracts, and 40-country distribution network
3. **Cost Efficiency**: COGS target 60-70%, SG&A reduction initiatives
4. **Oncology Pipeline**: Phase Ib nitric oxide therapy trial for glioblastoma and autism expected to begin H2 2026

Beyond Air, Inc. (XAIR) Q3 2026 Earnings Call Transcript

- **Revenue Surge**: Q2 2026 revenue up 128% YoY to $1.8 million, with FY26 guidance of $8-10 million.
- **Gen II Momentum**: Second-gen LungFit PH (FDA pending) set for late 2026 launch, targeting larger hospitals and transport use.
- **Global Expansion**: 35+ country partnerships, first international placements, targeting 60+ countries by end-2026.
- **Financial Strength**: $12M debt + $20M equity line provides runway to profitability, with 66% YoY cash burn reduction.
- **Clinical Progress**: Beyond Cancer trial shows 22-month median survival; NeuroNOS programs advance with FDA orphan designations.

**【CEO Summary Section】**
- **Revenue Growth**: Q2 2026 revenue reached $1.8 million, up 128% YoY and 3% sequentially. FY26 guidance updated to $8-10 million.
- **New Sales Model**: Introduced capital purchase option for LungFit PH, with first hospital purchase post-quarter end. This complements traditional leasing model.
- **International Expansion**: Placed first commercial systems outside the U.S. in Japan, South Korea, and Latin America, expanding to 35 countries. Target 60+ countries by end-2026.
- **Gen II Launch**: Second-generation LungFit PH (smaller, portable) expected to launch late 2026 (pending FDA approval). Gen II design patent granted through 2040.
- **Clinical Updates**: Beyond Cancer's Phase Ia trial shows median survival of 22 months (UNO therapy). NeuroNOS programs (BA-101, BA-102) advance with FDA orphan drug designations.
- **Financial Strength**: Secured $12M debt and $20M equity line with Streeterville Capital, providing runway through 2027.

**【CFO Financial Commentary】**
- **Revenue & Margin**: Q2 2026 revenue $1.8M (vs. $0.8M YoY). Gross loss narrowed to $0.3M (from $1.1M YoY) due to sales growth, offset by inventory/write-down costs.
- **Cost Control**: Total operating expenses down 37% YoY to $7.4M. R&D expenses halved to $2.5M, SG&A reduced 32% to $4.9M. Cash burn reduced 66% YoY to $4.7M.
- **Liquidity**: $10.7M cash as of Q2, with $32M+ available via debt/equity lines. Expect cash burn to decline as revenue grows.

**【Q&A Highlights】**
- **Gen II Growth Drivers**: International expansion (35+ countries with partners) and U.S. capital sales model adoption. FDA approval delays attributed to supply chain, not regulatory hurdles.
- **FDA Timeline**: Gen II launch expected late 2026, contingent on FDA approval. No material delays noted; focus on supply chain readiness.
- **Business Model Impact**: Capital purchases reduce reliance on leasing cycles, offering hospitals cost flexibility. Early feedback on Gen II design positive.
- **International Pricing**: Ex-U.S. sales via distributors, with disposables revenue similar to U.S. model. Regulatory approvals in key markets expected to drive 2027+ growth.
- **Contract Renewals**: Hospitals extending contracts with multiyear agreements, reflecting LungFit PH's value proposition. No significant attrition reported.

Beyond Air, Inc. (XAIR) Q2 2026 Earnings Call Transcript

- **Revenue Surge**: Q1 FY2026 revenue up 157% YoY to $1.8M, driven by LungFit PH adoption and multiyear contracts.
- **Cost Efficiency**: Operating expenses reduced 40% YoY to $7.5M, with net loss narrowing to $7.7M.
- **Market Expansion**: Access to 30+ countries and ~3,000 hospitals via GPOs, with LungFit PH II FDA approval on horizon.
- **Guidance Confidence**: Reaffirmed $12M-$16M FY2026 target, supported by international partner ramp and GPO wins.
- **Cash Position**: $6.5M cash as of June 2025, enabling operations into 2026 with path to profitability.

**【CEO Summary Section】**
- **Revenue Growth**: Q1 FY2026 revenue increased 157% YoY to $1.8 million, driven by LungFit PH adoption. Sequential growth was 50% from Q4 FY2025.
- **Contract Strength**: 55% of contracts are multiyear; international revenue began contributing this quarter.
- **Market Expansion**: Access to over 30 countries via distribution partners covering 2 billion lives. Added to Premier GPO, providing access to ~3,000 hospitals.
- **Guidance Reaffirmation**: Maintained FY2026 revenue guidance of $12M-$16M, with FY2027 momentum expected.
- **Product Pipeline**: LungFit PH II (smaller, transportable) FDA approval anticipated, targeting majority market share in $1B NO market.

**【CFO Financial Commentary】**
- **Revenue & Profitability**: Gross profit improved to $0.2M (vs. -$0.3M YoY), driven by revenue growth and device depreciation.
- **Cost Efficiency**: Operating expenses reduced 40% YoY to $7.5M, with R&D down 48% and SG&A down 35%. Net loss narrowed to $7.7M (vs. $12.2M YoY).
- **Cash Management**: Net cash burn decreased 60% YoY to $4.7M. Cash balance of $6.5M as of June 30, 2025, supporting operations into 2026.

**【Q&A Key Highlights】**
- **Growth Drivers**: Confidence in hitting FY2026 guidance through new contracts, Premier GPO wins, and international partner ramp-up.
- **International Momentum**: Early-stage tender wins expected in FY2026, with full impact in FY2027. Training devices shipped to partners for hospital demos.
- **Expense Modeling**: Q2 expenses ~$7.5M, with potential increase in Q4 tied to revenue growth. No plans to reinflate costs beyond commercial needs.
- **Premier Impact**: GPO streamlines sales process, but FY2026 impact limited; FY2027 expected to see significant acceleration.
- **Contract Renewals**: Hospitals using more NO hours may seek longer-term contracts, offering upside beyond base guidance.

Beyond Air, Inc. (XAIR) Q1 2026 Earnings Call Transcript

- **Revenue Surge**: FY2025 up 220% to $3.7M; FY2026 guided $12-16M, driven by U.S. hospital contracts and international expansion.
- **Innovation Momentum**: LungFit PH II PMA filed; Gen 1 adoption accelerates with 45+ U.S. hospitals and initial OUS shipments.
- **Financial Discipline**: FY2025 cash burn down 28%; operating expenses reduced 58% over 6 quarters, positioning for 2026 profitability.
- **Pipeline Breakthroughs**: NeuroNOS autism therapy gains Orphan Drug status; Beyond Cancer enters Phase Ib trial in Israel.

**【CEO Summary Section】**
- **Revenue Growth**: FY2025 revenue surged 220% to $3.7 million, with FY2026 guidance of $12-16 million. Q4 2025 revenue expected to reach $1.7 million, up 145% YoY.
- **Product Expansion**: Submitted PMA supplement for LungFit PH II, a smaller, transport-friendly system. Expanded international reach with 20+ country partnerships, including India, Italy, and Ukraine.
- **Subsidiary Progress**: Beyond Cancer secured Phase Ib trial approval in Israel; NeuroNOS received Orphan Drug Designation for autism treatment and published breakthrough Alzheimer's research.
- **Leadership Update**: Appointed Bob Goodman to Board, bringing healthcare industry expertise.

**【CFO Financial Commentary】**
- **FY2025 Financials**: Revenue $3.7 million vs. $1.2 million prior year; COGS $5.4 million due to device depreciation. Net loss $46.6 million, with cash burn down 28% to $44.1 million.
- **Cost Efficiency**: R&D expenses reduced $7.5 million, SG&A cut $11.3 million. Operating expenses down 58% over 6 quarters, targeting trough in Q2 2025.
- **Liquidity**: $6.9 million cash as of March 31, plus $3 million post-period funding, supporting operations into 2026.

**【Q&A Key Points】**
- **LungFit PH II Launch**: FY2026 guidance excludes Gen 2 contributions; approval timing uncertain but Gen 1 remains focus.
- **International Dynamics**: OUS sales face tender processes; initial shipments for demos, with hospital placements expected H2 2025.
- **Competitive Landscape**: Unaffected by Mallinckrodt's new cylinder-based system; unique cylinder-free model maintains differentiation.
- **Financial Confidence**: FY2026 guidance driven by U.S. contract growth and international expansion; cost control and razor-razorblade model adoption provide upside.

Beyond Air, Inc. (XAIR) Q4 2025 Earnings Call Transcript

- **Revenue momentum**: 6 new U.S. hospital starts and 2 renewals drive sequential growth
- **Next-gen product**: FDA submission for transport-capable LungFit PH expected shortly; strong hospital demand
- **Global expansion**: CE Mark triggers $1M milestone; 2 Middle East contracts signed
- **Cost control**: Q3 cash burn down 30% YoY; further reductions expected in Q4
- **Beyond Cancer progress**: Phase Ib trial with ultra-high concentration NO targeting end-2025 readout
- **NeuroNOS advancement**: Gene therapy for Autism Spectrum Disorders with FDA meeting planned for 2025

**【CEO Summary Section】**
- Sequential quarterly revenue growth driven by 6 new hospital starts and 2 renewals (1 for 3 years) in the U.S. 
- Next-gen LungFit PH system with transport capability set for FDA submission; received strong feedback at AARC meeting with hospitals asking, "When can I get this version?"
- CE Mark approval for Europe granted in December, triggering $1M milestone payment from Getz Healthcare; already signed 2 contracts in the Middle East
- Global expansion strategy includes partnerships with healthcare links, TrillaMed (military hospitals), and business Asia consultants
- Beyond Cancer Phase Ib trial for ultra-high concentration nitric oxide (UNO) in late-stage cancer patients expected to report top-line data by end-2025
- NeuroNOS subsidiary advancing gene therapy for Autism Spectrum Disorders with FDA meeting planned for 2025

**【CFO Financial Commentary】**
- Q3 FY2025 revenue: $1.1M (vs. $0.4M YoY), gross loss: $0.2M (vs. $0.4M YoY)
- R&D expenses: $3M (down $3.8M YoY due to salary and stock-based comp reductions)
- SG&A expenses: $7.7M (down $2.1M YoY from salary and comp cuts)
- Net loss: $13M (vs. $16.2M YoY); cash burn: $7.6M (30% lower than prior quarter)
- Cash position: $10.9M as of Dec 31, 2024; expects to fund operations through spring 2026
- One-time costs of $0.3M for device upgrades and $0.5M non-cash depreciation impacted COGS

**【Q&A Key Takeaways】**
- CE Mark impact: Minimal in Q1 2025, small contribution in Q2, significant ramp in H2 2025
- Cost reductions: June quarter will show steeper drop than March quarter
- FDA timeline uncertainty: FDA staff turnover and resource constraints make approval timing unpredictable
- International strategy: Focus on regions with logistical challenges for cylinder-based NO (e.g., Middle East, Asia Pacific)
- Revenue visibility: Sequential growth expected to continue, with guidance for FY2026 to be provided in June
- PMA supplement for cardiac surgery: Interactive discussions ongoing; no timeline visibility
- Beyond Cancer: Phase Ib trial with 25,000 ppm UNO in anti-PD-1 refractory patients targeting end-2025 readout

Actual					-7.2	-8	-6	-4.8	-6.2	-7.2	-5.8	-13.4	-7.4	-8	-8.6	-13.2	-9	-10.2	-10	-7.2	-5.4	-5.6	-3	-1.8	-1.53	-1.25	-0.85
Forecast					-7.9	-6.25	-6.1	-6.16	-4.28	-5.56	-5.2	-5.32	-9.35	-7.4	-8.28	-9.7	-9.3333	-9.381	-10.8	-9.48	-6.338	-5.68	-3.188	-2.44	-1.228	-0.7733	-0.7505
Surprise	0.00%	0.00%	0.00%	0.00%	+8.86%	-28.00%	+1.64%	+22.08%	-44.86%	-29.50%	-11.54%	-151.88%	+20.86%	-8.11%	-3.86%	-36.08%	+3.57%	-8.73%	+7.41%	+24.05%	+14.80%	+1.41%	+5.90%	+26.23%	-24.59%	-61.64%	-13.26%

Actual	--	--	--	--	-197.35K	229.16K	349.61K	143.19K	0	0	0	0	0	0	0	0	59.00K	240.00K	391.00K	469.00K	683.00K	798.00K	1.07M	1.15M	1.76M	1.82M	2.19M
Forecast	--	--	--	--	406.67K	206.67K	156.67K	311.00K	325.00K	75.00K	0	0	0	0	0	526.00K	331.50K	475.97K	449.20K	743.20K	798.00K	1.03M	935.86K	1.38M	2.59M	2.15M	2.15M
Surprise	0.00%	0.00%	0.00%	0.00%	-148.53%	+10.88%	+123.15%	-53.96%	-100.00%	-100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-100.00%	-82.20%	-49.58%	-12.96%	-36.89%	-14.41%	-22.55%	+14.55%	-16.42%	-32.03%	-15.27%	+1.70%

XAIR

XAIR fundamentals

XAIR Q3 2026 Earnings

Earnings Call

You can ask Aime

XAIR

XAIR fundamentals

XAIR Q3 2026 Earnings

Earnings Call

XAIR Earnings Call Summary for Q3/20268:00 AM on Feb 13, 2026

XAIR Earnings Call Summary for Q2/20264:30 PM on Nov 10, 2025

XAIR Earnings Call Summary for Q1/20264:30 PM on Aug 12, 2025

XAIR Earnings Call Summary for Q4/20254:30 PM on Jun 17, 2025

XAIR Earnings Call Summary for Q3/20254:30 PM on Feb 10, 2025

You can ask Aime